An observational study of ALK-IHC screening for advanced or metastatic solid tumors(WJOG15221MPS)

An observational study of ALK-IHC screening for advanced or metastatic solid tumors(WJOG15221MPS) - An observational study of ALK-IHC screening

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050330

Enrollment

5000

Registered

2023-02-14

Start date

2023-04-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or metastatic solid tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histopathologically confirmed diagnosis of solid tumor 2) advanced or metastatic solid tumors 3) Chemotherapy is being or is scheduled to be administered 4) Expected to survive at least 12 weeks 5) Written consent has been obtained. 6) Tumor tissue samples can be submitted

Exclusion criteria

Exclusion criteria: 1) Patients diagnosed with non-small cell lung cancer 2) Patients considered unsuitable to be enrolled in this study by their attending physicians

Design outcomes

Primary

Measure	Time frame
Examine the positivity ratio of ALK-IHC in solid tumors	—

Secondary

Measure	Time frame
The proportion of patients with IHC test results and their prognosis will also be examined.	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results